ライフサイエンスコーパス: GRP

1 GRP antagonists should be considered for further develop

2 GRP blockade diminished serine phosphorylation of GRPR w

3 GRP blockade is a novel radiation fibrosis mitigating ag

4 GRP blockade with 77427 treatment diminished CD68(+), GR

5 GRP had the same effects as bombesin, whereas neither NM

6 GRP is a tissue equivalent to the mouse node, in which c

7 GRP may be a target for novel therapies to reduce the ri

8 GRP receptor expression was increased in the spinal cord

9 GRP stimulated contractions acutely when added to freshl

10 GRP-R expression of 50 clinical BC specimens and the cor

11 GRP-R expression was also analyzed in 9 BC cell lines ap

12 GRP-R knockdown also up-regulated the expression of tumo

13 GRP-R tumor expression was positively (P = 0.026, chi(2)

14 GRPs also extended survival and disease duration, attenu

15 GRPs survived in diseased tissue, differentiated efficie

16 The SARNC ([(N4)Gly(18)]GRP(18-27)) analogs (SARNC2 dAla(24), SARNC3 dAla(24)/Nl

17 Compound 1a (GRP-74915) was selected for development based on activit

18 (Bmax) of 414 fmol/10(6) cells (2.5 x 10(5) GRP-R/cell).

19 n 1 (XBP1) and glucose-regulated protein 78 (GRP 78), and nuclear translocation of activating transcr

20 Glucose-regulated protein-78 (GRP-78) is an endoplasmic reticulum chaperone protein th

21 binding to the glucose-regulated protein-78 (GRP-78) localized on the plasma membrane of preodontobla

22 r colony formation, which was inhibited by a GRP-blocking antibody.

23 depletion or neutralization of TNF abrogates GRP-induced neutrophil recruitment to the peritoneum.

24 this article we demonstrate that abrogating GRP/GRPR signaling specifically down-regulates HP1(Hsbet

25 f a known smooth muscle stimulatory agonist, GRP.

26 Although GRP is known to participate in meal-stimulated acid secr

27 pes of CSPG printed on cover glass, although GRPs were still responsive to the remaining repulsive si

28 ows: SAP, 2.177; SWAP, 1.96; FDP, 1.277; and GRP, 1.04.

29 P, 4.85 dB; SWAP, 9.03 dB; FDP, 4.29 dB; and GRP, 1.36 dB.

30 confirm spatial co-localization of DMP1 and GRP-78 in the preodontoblasts of a developing mouse mola

31 endently attenuates both beta-endorphin- and GRP-elicited robust scratching without affecting pain pr

32 ed trained observers for SAP, SWAP, FDP, and GRP.

33 Our findings demonstrate that GRP and GRP-R have important oncogenic properties beyond their e

34 Coactivation of 5-HT1A and GRP receptors (GRPR) greatly potentiates subthreshold, G

35 e, combined treatment with neurotrophins and GRP grafts can facilitate functional recovery after trau

36 Thus, we propose that NMB and GRP may transmit discrete itch information and NMBR neur

37 nistration, beta-endorphin (10-100 nmol) and GRP (1-10 nmol) dose-dependently elicit the same degree

38 ited by mu-opioid peptide (MOP) receptor and GRP receptor (BB2) antagonists, respectively.

39 g effects by beta-endorphin-MOP receptor and GRP-BB2 receptor systems and itch-inhibiting effects by

40 GRP antiserum in tissues from wild-type and GRP mutant mice indicates that the antiserum is only sel

41 ivocal evidence that AuNP-BBN constructs are GRP-receptor-specific showing accumulation with high sel

42 Furthermore, silencing GRP-R as well as GRP in BE(2)-C cells suppressed anchorage-independent gr

43 test whether AP5 would be able to attenuate GRP-induced shifts 15 min following microinjection of GR

44 tivation with decoy oligonucleotides blocked GRP-induced phase shifts of PER2::luciferase rhythms in

45 High-affinity receptors for BN/GRP were found on tumors.

46 Western blot analaysis, and receptors for BN/GRP were investigated by radioligand-binding studies.

47 Our findings demonstrate the efficacy of BN/GRP antagonist RC-3940-II for the treatment of NSCLC.

48 The effect of the administration of BN/GRP antagonist RC-3940-II on the growth of H460 and A549

49 ght contribute to the antitumor action of BN/GRP antagonists.

50 We evaluated whether antagonists of BN/GRP can suppress the growth of human non-SCLC (NSCLC) xe

51 Antagonists of BN/GRP have been shown to inhibit these cancers.

52 Bombesin/GRP can induce features of BPD, including interstitial f

53 bolism, were also significantly decreased by GRP-R silencing.

54 rvival and metastasis, was down-regulated by GRP-R silencing.

55 ade with 77427 treatment diminished CD68(+), GRP(+), and pSmad2/3(+) cells.

56 rd-derived glial-restricted precursor cells (GRPs), which differentiate into both oligodendrocytes an

57 In conclusion, GRP antagonists reduce volume of human prostatic cells a

58 In contrast, GRP/GRPR can be aberrantly expressed in colon cancer whe

59 ffect in promoting the migration of cultured GRPs.

60 also significantly enhanced only in the D15A-GRP-grafted animals at 4 and 5 weeks after transplantati

61 In addition, RHBDF1 gene silencing disrupts GRP-stimulated secretion of EGFR ligand TGF-alpha, but n

62 xenografts in SCID mice, with [(111)In-DOTA]GRP(17-27) exhibiting the most favorable pharmacokinetic

63 The shorter chain [(111)In-DOTA]GRP(17/18-27) analogs showed higher metabolic stability

64 essing Foxj1 is sufficient to induce ectopic GRP-like cilia formation in frog embryos.

65 unable to demonstrate a role for endogenous GRP in meal-stimulated gastrin secretion in humans.

66 Enhanced GRP expression and sustained ERK phosphorylation were ob

67 ed with the plasmid pEGFP-GRP-R to establish GRP-R overexpression cell lines, and the effects of GRP

68 acrophages, T cells, and neutrophils express GRP receptor (GRPR).

69 ficial dorsal horn interneurons that express GRP and that likely target GRPR-expressing interneurons.

70 nd BC cell lines (6/9) were found to express GRP-R.

71 RP produced aggressive tumors, which express GRP, prostate-specific antigen, and nuclear-localized AR

72 that the descending 5-HT system facilitates GRP-GRPR signaling via 5-HT1A to augment itch-specific o

73 tes that the antiserum is only selective for GRP at high dilutions.

74 (either directly purified or generated from GRP cells).

75 rcentage of APC+ oligodendrocytes of grafted GRPs (15-30%).

76 astructural analysis showed that the grafted GRPs formed morphologically normal-appearing myelin shea

77 A gastrin-releasing peptide (GRP)/GRP receptor-mediated autocrine pathway was previously d

78 mmunoreactive terminals, altered dorsal horn GRP immunoreactivity.

79 However, GRP, which is known to be limited by retinal sampling ra

80 otected N(4)-chelator to neuromedin C (human GRP(18-27)), which, after (99m)Tc-labeling, afforded [(9

81 study has demonstrated the efficacy of human GRP-based radiopeptides to target GRPR-positive lesions

82 perspectives of radioligands based on human GRP sequences in the detection and therapy of GRPR-expre

83 Thus, human GRP-based radioligands, such as [(99m)Tc]Demomedin C, ca

84 recently expanded this approach toward human GRP(18-27) sequences and introduced (99m)Tc-demomedin C,

85 chains of CSPG with chondroitinase improved GRP migration on stripes of CSPG printed on cover glass,

86 2 and the posterior localization of cilia in GRP cells, demonstrating its role in PCP.

87 ase in GRP binding capacity was confirmed in GRP-R overexpressing cells, which demonstrated an accele

88 key steps in mediating downstream events in GRP resetting of SCN neurons.

89 An increase in GRP binding capacity was confirmed in GRP-R overexpressi

90 An increase in GRP binding capacity, as a result of GRP-R overexpressio

91 n important regulatory mechanism involved in GRP-induced cell proliferation in neuroblastomas.

92 howing accumulation with high selectivity in GRP-receptor-rich pancreatic acne in normal mice and als

93 We infected GRPs with retroviruses expressing the multineurotrophin

94 th antisense oligodeoxynucleotides inhibited GRP-induced increases in spike frequency.

95 we demonstrate that the receptor for DMP1 is GRP-78.

96 including glucose regulated protein-78 kDa (GRP-78), heterogeneous nuclear ribonucleoprotein (hnRNP)

97 CaP cells and the resultant cell line, LNCaP-GRP, exhibited androgen-independent growth with enhanced

98 ally implanted in castrated nude mice, LNCaP-GRP produced aggressive tumors, which express GRP, prost

99 romatin immunoprecipitation studies of LNCaP-GRP clones suggest that GRP activates and recruits AR to

100 and imaging potential of (177)Lu-AMBA in low GRP-R models of prostate cancer and determine how reduce

101 amount of intraspecific polymorphism in male GRPs may be a consequence of the relative efficiency of

102 abeled truncated analogs of the human 27-mer GRP after conjugation of 1,4,7,10-tetraazacyclododecane-

103 In both models, GRP blockade abrogated AHR and bronchoalveolar lavage (B

104 BALB/c mice were given small molecule GRP blocking agent 77427, or GRP blocking antibody 2A11,

105 Moreover, GRP-R deficiency significantly delayed tumor growth and

106 d fear acquisition and expression in a mouse GRP.

107 learning and highlight the utility of mouse GRPs for the identification of genes underlying complex

108 that peripheral nerve injury induced de novo GRP expression in DRG neurons points to a novel contribu

109 NRP/GRP grafts also produced greater recovery of hindlimb fu

110 NRP/GRP with and without NBQX produced a significant recover

111 a developed in both operated groups, but NRP/GRP recipients exhibited an accelerated recovery, with d

112 uggest that local protection provided by NRP/GRP resulted in increased sparing/sprouting of descendin

113 ated groups, and micturition pressure in NRP/GRP rats recovered to normal levels.

114 e of spinal cord spared was increased in NRP/GRP recipients, suggesting local protection.

115 Nine days post-injury, NRP/GRP were delivered into the lesion site.

116 We found that mixed NRP/GRP grafts can be efficiently delivered to a cervical he

117 Similarly, NBQX&NRP/GRP induced more spouting, regeneration or sparing of de

118 s receiving the combined treatment (NBQX&NRP/GRP) had voided volumes/micturition resembling that of n

119 mbined treatments was similar to that of NRP/GRP alone with decreased sprouting of primary afferents

120 In conclusion, transplants of NRP/GRP combined with NBQX promote recovery of micturition f

121 euronal and glial restricted precursors (NRP/GRP) derived from the embryonic spinal cord of alkaline

122 euronal and glial restricted precursors (NRP/GRP) into a midthoracic injury 9 d after contusion impro

123 Controls received NRP/GRP grafts only or no treatment (OP-Controls).

124 e of the lesion to a greater extent than NRP/GRP alone or OP-Controls.

125 Histological analysis showed that NRP/GRP survived, filled the lesion site, differentiated int

126 factor-positive fibers increased in the NRP/GRP group compared with OP-controls, suggesting some spa

127 e OP-controls but appeared normal in the NRP/GRP group.

128 nt of urodynamic parameters, compared to NRP/GRP alone or OP-Controls.

129 ect parenchymal injections, transplanted NRP/GRP cells survive at the injury cavity for at least 5 we

130 Addition of GRP increases endothelial cell migration and cord format

131 on of AP5 15 min after the administration of GRP were not different from those that received microinj

132 ed significantly with an excessive amount of GRP antagonists.

133 have demonstrated that potent antagonists of GRP inhibit growth of experimental human tumors includin

134 this study was to explore the application of GRP-R radioligands for imaging and therapy of BC by intr

135 ow that Pk3 is enriched at the basal body of GRP cells but is recruited by Vangl2 to anterior cell bo

136 hese findings suggest a signaling cascade of GRP-Src-PI3-K-PDK1-TACE-amphiregulin-EGFR with multiple

137 Here we examine the effect of GRP on both molecular and behavioral properties of the h

138 Here, we evaluated the effects of GRP antagonist RC-3940-II on viability and cell volume o

139 However, the effects of GRP on expression of the tumor suppressor gene PTEN have

140 verexpression cell lines, and the effects of GRP on PTEN gene and protein expression were determined.

141 All effects of GRP were abrogated in GRPR-null mice.

142 GRPR appears to mediate all effects of GRP, but only part of the bombesin effect on alveolariza

143 uman neuroblastomas; however, the effects of GRP/GRP-R on tumorigenesis and metastasis in vivo are no

144 Differential expression of GRP-78 mRNA and protein was observed upon in vitro diffe

145 umor cell line has an elevated expression of GRP-Rs (2.5 x 10(5)/cell), whereas LNCaP--a prostate can

146 paradigm shift in the biological function of GRP-78.

147 e selective uptake of this new generation of GRP-receptor-specific AuNP-BBN peptide analogs has demon

148 ting protein carbonyls with the hydrazide of GRP.

149 sions in vivo and has revealed the impact of GRP chain length on key biological parameters of resulti

150 APK and AKT, accompanied by an inhibition of GRP-induced survival, proliferation, and invasion of the

151 Here we demonstrate that i.p. injection of GRP attracts neutrophils in 4 h, and attraction is block

152 The intrathecal injection of GRP led to intense scratching, an effect largely reduced

153 er cell lines expressing different levels of GRP and integrin receptors, and their intracellular loca

154 We have synthesized a library of GRP receptor-avid nanoplatforms by conjugating gold nano

155 demonstrate the cell surface localization of GRP-78 and provide evidence that it functions as a recep

156 t from those that received microinjection of GRP and vehicle.

157 ed shifts 15 min following microinjection of GRP.

158 In vivo microinjections of GRP to the SCN regions of Per1::green fluorescent protei

159 Conversely, overexpression of GRP-R in less aggressive SK-N-SH neuroblastoma cells res

160 Up-regulation of GRP mRNA by stretch was confirmed in a separate series o

161 ease in GRP binding capacity, as a result of GRP-R overexpression, down-regulates PTEN expression.

162 Here, we tested the putative role of GRP as an intra-SCN light signal at the behavioral and c

163 In the present study we explored the role of GRP-78 in mineralized matrix formation.

164 mechanism(s) mediating the oncogenic role of GRP/GRP-R and demonstrates a novel role for AKT2 in neur

165 tetraacetic acid (DOTA) at the N-terminus of GRP(13/14/17/18-27) fragments.

166 ngly inhibited the adhesion and migration of GRPs, an effect that could be modulated by the adhesion

167 ssibility of producing a migratory stream of GRPs via directional cues to create a supportive pathway

168 -demomedin C, our first radiotracer based on GRP(18-27), showing favorable biologic characteristics d

169 c signal, but that this dependency ends once GRP-dependent signaling is complete.

170 small molecule GRP blocking agent 77427, or GRP blocking antibody 2A11, before exposure to ozone or

171 nt study tests whether exogenous bombesin or GRP given perinatally alters alveolar development in new

172 Inhibition of either BRAF or GRP signaling attenuated itch sensation in chronic itch

173 ow that itch deficits in mice lacking NMB or GRP are non-redundant and Nmb/Grp double KO (DKO) mice d

174 tocrine neuropeptide model by overexpressing GRP in LNCaP cells and the resultant cell line, LNCaP-GR

175 duces itch and attenuates inflammatory pain, GRP only elicits itch without affecting pain.

176 Mouse genetic reference panels (GRPs) provide one approach for identifying genetic sourc

177 re stably transfected with the plasmid pEGFP-GRP-R to establish GRP-R overexpression cell lines, and

178 an inhibition of gastrin-releasing peptide (GRP) -induced phosphorylation of EGFR and EGFR-dependent

179 tes targeting the gastrin-releasing peptide (GRP) and integrin receptors is reported.

180 The gastrin-releasing peptide (GRP) and its receptor (GRPR) are important components of

181 ations induced by gastrin-releasing peptide (GRP) and its receptor, GRP-R, in neuroblastoma.

182 genes, including gastrin-releasing peptide (GRP) and MAS-related GPCR member A3 (MRGPRA3), in nocice

183 these processes: gastrin-releasing peptide (GRP) and the small conductance, calcium-activated potass

184 Bombesin (BN) or gastrin-releasing peptide (GRP) can stimulate the growth of neoplasms such as breas

185 polypeptide (VIP)/gastrin-releasing peptide (GRP) cells located ventrally in the SCN receive retinal

186 ated peptides and gastrin-releasing peptide (GRP) in awake, behaving monkeys.

187 microinjection of gastrin-releasing peptide (GRP) into the third ventricle or near the suprachiasmati

188 Gastrin-releasing peptide (GRP) is a neuropeptide that acts through G protein coupl

189 es suggested that gastrin-releasing peptide (GRP) is an itch-specific neurotransmitter.

190 Gastrin-releasing peptide (GRP) is localized to the SCN ventral retinorecipient zon

191 Gastrin-releasing peptide (GRP) is synthesized by pulmonary neuroendocrine cells in

192 normally express gastrin-releasing peptide (GRP) or its receptor (GRPR).

193 Gastrin-releasing peptide (GRP) receptors (GRPr) are frequently overexpressed in hu

194 h affinity toward gastrin-releasing peptide (GRP) receptors in vivo that are overexpressed in prostat

195 iously shown that gastrin-releasing peptide (GRP) stimulates neuroblastoma growth, and that its cell

196 Two probes for gastrin-releasing peptide (GRP), a known stimulatory agonist of smooth muscle, were

197 SCN neuropeptide, gastrin-releasing peptide (GRP), can acutely enhance and synchronize molecular time

198 (CART), galanin, gastrin-releasing peptide (GRP), neuropeptide Y (NPY), nitric oxide synthase (NOS),

199 Gastrin-releasing peptide (GRP), secreted by pulmonary neuroendocrine cells, mediat

200 al peptide (VIP), gastrin-releasing peptide (GRP), substance P, and calcitonin gene-related peptide (

201 Exemplified by gastrin-releasing peptide (GRP), these neuropeptides transmit their signals through

202 r in facilitating gastrin-releasing peptide (GRP)-dependent scratching behavior.

203 was also found on gastrin-releasing peptide (GRP)-positive neurons (pruriceptive fibers), and AYP-ind

204 pressin (AVP) and gastrin-releasing peptide (GRP).

205 neurotransmitter, gastrin-releasing peptide (GRP).

206 A gastrin-releasing peptide (GRP)/GRP receptor-mediated autocrine pathway was previou

207 Gastrin releasing-peptide (GRP) is a potent growth factor in many malignancies.

208 mmalian bombesin (gastrin-releasing peptide [GRP]) drop postnatally, but these levels are elevated in

209 ctor IGF-1] and three A10-elevated peptides (GRP, CGRP and PACAP) were further examined in both alpha

210 erning on the Xenopus gastrocoel roof plate (GRP) and zebrafish Kupffer's vesicle are severely shorte

211 leftward flow at the gastrocoel roof plate (GRP), and aberrant expression of both Coco and Pitx2c we

212 a Prickle, in Xenopus gastrocoel roof plate (GRP).

213 rker map for a genetic reference population (GRP) that consists of 32 BXD strains of mice made by int

214 rogenitor cells, glial-restricted precursor (GRP) cells and oligodendrocyte/type-2 astrocyte progenit

215 cursors, called glial-restricted precursors (GRPs).

216 Efficacy in SCLC and the utility of pro-GRP as a marker of treatment response will be further ev

217 Pro-gastrin releasing peptide (pro-GRP) was identified as a surrogate marker of Bcl-2 ampli

218 splantation of glial-restricted progenitors (GRPs) is a promising strategy for generating a supportiv

219 rough direct inhibitory effects on prostatic GRP receptors.

220 gression requires glucose regulated protein (GRP) 78 for cancer cell survival and proliferation, as w

221 Glucose Regulated Protein (GRP) 94 and GRP78 are critical molecular chaperones and

222 ticulum chaperone glucose-regulated protein (GRP) 94.

223 haperones such as glucose-regulated protein (GRP) and protein-disulphide isomerase (PDI), which assis

224 d divergence of gamete recognition proteins (GRPs) can result in reproductive isolation.

225 Two new classes of radiolabeled GRP receptor antagonists are studied and compared with t

226 of oxidized proteins with Girard P reagent (GRP; 1-(2-hydrazino-2-oxoethyl)pyridinium chloride), (2)

227 -coupled gastrin-releasing peptide receptor (GRP-R) and is currently in phase I clinical trials.

228 ting the gastrin-releasing peptide receptor (GRP-R) might offer a specific method for imaging and the

229 in-releasing peptide (GRP) and its receptor, GRP-R, in neuroblastoma.

230 growth, and that its cell surface receptor, GRP-R, is overexpressed in advanced-stage human neurobla

231 Gastrin-releasing peptide receptors (GRP-R) are upregulated in many cancers, including prosta

232 apitulated by chemogenetic inhibition of SCN GRP neurons.

233 Activation of SCN GRP/GRPR neurons evoked scratching behavior.

234 YP-induced itch was reduced by the selective GRP receptor antagonist RC-3095.

235 Seven GRP-derivatized peptides were found to be selected from

236 peripheral nerve injury induced significant GRP expression in a heterogeneous population of DRG neur

237 Furthermore, silencing GRP-R as well as GRP in BE(2)-C cells suppressed anchora

238 ors (GRPR) greatly potentiates subthreshold, GRP-induced Ca(2+) transients, and action potential firi

239 to produce a migratory stream of supportive GRPs.

240 Targeting GRP-R-expressing BC tumors using GRP-R radioligands is p

241 , and immunohistochemistry, we conclude that GRP is expressed abundantly in spinal cord, but not in D

242 We also confirmed that GRP-R is upstream of AKT2 and in turn, regulated N-myc e

243 Considering that GRP blockade abrogates pulmonary inflammation and fibros

244 Our findings demonstrate that GRP and GRP-R have important oncogenic properties beyond

245 These data demonstrate that GRP-GRPR signaling is necessary and sufficient for trans

246 We provide evidence that GRP-78 can bind to DMP1 and type I collagen independent

247 In the present study, we found that GRP-R knockdown in the aggressive cell line BE(2)-C indu

248 To test the hypothesis that GRP mediates asthma, we used two murine models: ozone ex

249 Altogether, these results indicate that GRP communicates phase resetting signals within the SCN

250 of calcium and phosphate ions indicated that GRP-78 can induce the formation of calcium phosphate pol

251 Our data are the first to show that GRP blockade decreases inflammatory and fibrotic respons

252 Our data show that GRP directly activates small-size capsaicin-sensitive DR

253 g and retrograde tracing studies showed that GRP-expressing neurons of the superficial dorsal horn ar

254 ion studies of LNCaP-GRP clones suggest that GRP activates and recruits AR to the cognate promoter in

255 airway inflammation in mice, suggesting that GRP blockade is promising as a broad-spectrum therapeuti

256 An interesting observation was that GRP-78 was identified in the secretome of these cells an

257 amma (PKCgamma), but that none coexpress the GRP receptor (GRPR).

258 177Lu-AMBA has a high affinity for the GRP-R (Kd, 1.02 nmol/L), with a maximum binding capacity

259 nged incubation of stretched explants in the GRP antagonists PD-176252 or RC-3095 (65 and 24 h, respe

260 y during time, the absorbance at 420 nm, the GRP (grape reaction products) and hydroxycinnamic acids

261 Western blot demonstrated expression of the GRP receptor in 9 out of a further 9 cases.

262 n experiments confirm the involvement of the GRP receptor in both the phototherapeutic activity as we

263 ogen-independent growth and migration of the GRP-expressing cell lines, and blocks the nuclear transl

264 D and MCF7 xenografts after injection of the GRP-R antagonist (111)In-JMV4168.

265 situation, and little definitive work on the GRP-R status of primary prostate tumors and metastases e

266 xicity of (177)Lu-AMBA was determined on the GRP-R-expressing BC cell line T47D.

267 therapy (PDT) of cancers overexpressing the GRP receptor.

268 tumorigenesis, indicating that targeting the GRP/GRP-R/AKT2 axis may be important for developing nove

269 We found that the GRP receptor antagonist RC-3059 and the SK2 specific blo

270 studied by in vitro autoradiography with the GRP-R agonist (111)In-AMBA.

271 onal polymorphisms that segregate within the GRP.

272 Therefore, GRP-R may be an ideal therapeutic target for the treatme

273 uences of mammary-targeted knockout of these GRPs.

274 Furthermore, this GRP blocker was able to reduce lung tumor cell growth in

275 Thus, GRP mediates AHR and airway inflammation in mice, sugges

276 177Lu-AMBA binds with nanomolar affinity to GRP-R and NMB-R, has low retention of radioactivity in k

277 (177)Lu-AMBA binds to GRP-R in these cell lines with high affinity (K(d) of LN

278 Binding of DMP1 to GRP-78 receptor was determined to be specific and satura

279 mbesin family of peptides closely related to GRP, but its role in itch is unclear.

280 K phosphorylation attenuates phase shifts to GRP.

281 toradiography, Lu-AMBA binds specifically to GRP-R (0.8 nmol/L) and to the neuromedin B receptor (NMB

282 ities (IC(50)) of AuNP-BBN conjugates toward GRP receptors on human prostate cancer cells have been i

283 We transplanted GRPs around cervical spinal cord respiratory motor neuro

284 with wild-type littermates, bombesin-treated GRP receptor (GRPR)-null mice had increased interstitial

285 ypothesized that ionizing radiation triggers GRP secretion, contributing to inflammatory and fibrotic

286 release of the EGFR ligand amphiregulin upon GRP treatment.

287 d kinase to directly phosphorylate TACE upon GRP treatment.

288 Titration of the most commonly used GRP antiserum in tissues from wild-type and GRP mutant m

289 Targeting GRP-R-expressing BC tumors using GRP-R radioligands is promising for nuclear imaging and

290 peptidergic cells of the SCN, including VIP, GRP, and arginine vasopressin (AVP) neurons, with each i

291 In vitro GRP application resulted in persistent increases in the

292 In vitro, GRP-induced neutrophil migration was dependent on PLC-be

293 When GRPs were transplanted into either normal spinal cord of

294 ernalization of both GRPR and MOR1D, whereas GRP specifically triggers GRPR internalization and morph

295 cellular levels, and we also tested whether GRP actions are dependent on activation of the cAMP resp

296 ransferrin, the protein was derivatized with GRP and trypsin digested.

297 Therefore, binding of DMP1 with GRP-78 receptor might be an important mechanism by which

298 Co-localization of DMP1 with GRP-78 was also observed in T4-4 preodontoblast cells, d

299 combined immunodeficient mice implanted with GRP-autocrine LNCaP cells.

300 Incubation of myometrium with GRP receptor antagonists attenuates the effect of stretc